Creatine transporter deficiency: prevalence among patients with mental retardation and pitfalls in metabolite screening
Since obesity is a chronic illness that can lead to type 2 diabetes, cardiovascular disease, certain cancers, and sleep disorders, the FDA responded by approving the use of semaglutide in increased dosages for treating obesity and overweight individuals with certain weight-related diseases
Front Endocrinol (Lausanne) 12:645507
Some small clinical trials have also shown encouraging results. In terms of alcohol miss-use, one study has shown that low dose semaglutide reduced an individuals number of drinking days
In fact, switching is unlikely to offer you any further benefits Can You Change Back?Yes, it may be possible to switch back to Wegovy injections if oral Wegovy does not suit you, but this must be done under a clinician's guidance